Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 15/20 | 0.74 |
| ▸ | SSTR2 | P30874 | 15/20 | 0.69 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.69 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.69 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31710298 | 1.00 | SSTR5 (0.74) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL30017399 | 1.00 | SSTR5 (0.74) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL29355620 | 1.00 | SSTR5 (0.74) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL29816803 | 0.94 | MC1R (0.68) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL30139822 | 0.94 | MC1R (0.68) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL29357154 | 0.94 | MC1R (0.68) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL29931190 | 0.87 | SSTR5 (0.89) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL3046369 | 0.87 | SSTR5 (0.89) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Tt-232 SCHEMBL16507741 | 0.87 | SSTR5 (0.84) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Tt-232 SCHEMBL29366660 | 0.87 | SSTR5 (0.84) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274794-B2 | Oral dosage form with drug composition, barrier layer and drug layer | ORIENT PHARMA CO., LTD. (TW) | 2025-04-15 | — | — | US | disclosed |
| US-11045465-B2 | Methods and compositions to prevent addiction | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3481381-A1 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | Durect Corporation (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-109475505-A | Peroral dosage form with pharmaceutical compositions, barrier layer and medicine layer | 度瑞公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2018009566-A1 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | DURECT CORPORATION (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-2983468-A1 | COMPOSITIONS WITH A RHEOLOGICAL MODIFIER TO REDUCE DISSOLUTION VARIABILITY | Durect Corporation (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2970253-A1 | COMPOSITIONS WITH THIXOTROPY AND ENHANCED DISSOLUTION REPRODUCIBILITY AND STABILITY | DURECT Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150352100-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | AVANT DERMA PTE. LTD. (SG) | 2015-12-10 | — | — | US | disclosed |
| CN-105120659-A | Compositions with a rheological modifier to reduce dissolution variability | DURECT CORP | 2015-12-02 | — | — | CN | disclosed |
| CN-105121438-A | Compositions with thixotropy and enhanced dissolution reproducibility and stability | DURECT CORP | 2015-12-02 | — | — | CN | disclosed |
| WO-2011020030-A9 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011020030-A2 | METHODS AND COMPOSITIONS TO PREVENT ADDICTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20090325857-A1 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | disclosed |
| CN-101426481-A | Use of opioid receptor antagonists | DSM IP ASSETS BV (NL) | 2009-05-06 | — | — | CN | disclosed |
| EP-2034977-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2009-03-18 | — | — | EP | disclosed |
| US-20090041687-A1 | Use of opioid receptor antagonists | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| CN-101272787-A | Use of opioid receptor antagonists | DSM IP ASSETS BV (NL) | 2008-09-24 | — | — | CN | disclosed |
| EP-1926490-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007121916-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007039058-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352100-A1 | USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS | OPRD1, OPRL1, OPRK1 | SSTR5 306/4885SSTR2 299/4885SSTR3 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.